US Probes Cheap Freight Rail Couplers from Czech Republic and India
Published Date: 7/29/2025
Notice
Summary
The U.S. is launching investigations to see if freight rail couplers from the Czech Republic and India are being unfairly sold or subsidized, which might hurt American businesses. If problems are found, extra taxes could be added to these imports. The first big decision is due by September 8, 2025, so things are moving fast!
Analyzed Economic Effects
2 provisions identified: 0 benefits, 1 costs, 1 mixed.
Investigations Could Lead to Import Duties
The U.S. has started antidumping and countervailing duty investigations into freight rail couplers and parts from the Czech Republic and India (HTS 8607.30.10). If the investigations find dumping or subsidization, extra duties (taxes) could be added to those imports; a preliminary decision is due by September 8, 2025 and the Commission must send its views to Commerce by September 15, 2025.
U.S. Industry Injury Review Scheduled
The Commission will decide whether a U.S. industry is materially injured or threatened with material injury by imports of freight rail couplers and parts from the Czech Republic and India that are alleged to be sold at less than fair value and alleged to be subsidized by the Government of India. That preliminary determination must be reached by September 8, 2025, with the Commission's views sent to Commerce by September 15, 2025.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16905, Certain Transformers and Components Thereof; Notice of Institution of Investigation
A company called Ayr Energy says some transformers and their parts imported into the U.S. are using stolen secrets and fake branding, which could hurt American businesses. The U.S. International Trade Commission is now investigating and might stop these products from being sold here. This could lead to new rules and orders soon, affecting companies selling these transformers and possibly changing what’s on store shelves.
2026-16848, Silicon Metal From Australia and Norway; Determinations
2026-16816, Hand Trucks and Certain Parts Thereof From China; Determination
2026-16811, Certain Ink Cartridges and Components Thereof II; Notice of a Commission Determination Finding a Violation Under Section 337; Issuance of a General Exclusion Order and Cease and Desist Orders; Termination of the Investigation
Notice is hereby given that the U.S. International Trade Commission has determined to find a violation under section 337 of the Tariff Act of 1930, as amended, and to issue a general exclusion order ("GEO") prohibiting the importation of products that infringe claims 1 and 7 of each of the following patents: U.S. Patent Nos. 8,764,172 ("the '172 patent"); 9,370,934 ("the '934 patent"); 11,535,038 ("the '038 patent"); 12,240,248 ("the '248 patent"); and 12,240,249 ("the '249 patent"); and cease and desist orders ("CDOs") against respondents Mountain Peak, Inc. and Straightouttaink, LP. The investigation is terminated.
2026-16667, Certain Mobile Electronic Devices; Notice of Institution of Investigation
Notice is hereby given that a complaint was filed with the U.S. International Trade Commission on July 10, 2026, under section 337 of the Tariff Act of 1930, as amended, on behalf of Maxell, Ltd. of Kyoto, Japan. An amended complaint was filed on July 24, 2026. The amended complaint alleges violations of section 337 based upon the importation into the United States, the sale for importation, and the sale within the United States after importation of certain mobile electronic devices by reason of the infringement of certain claims of U.S. Patent No. 10,812,646 ("the '646 patent"); U.S. Patent No. 12,513,408 ("the '408 patent"); U.S. Patent No. 12,061,760 ("the '760 patent"); U.S. Patent No. 12,418,692 ("the '692 patent"); U.S. Patent No. 12,185,211 ("the '211 patent"); and U.S. Patent No. 12,647,935 ("the '935 patent"). The amended complaint further alleges that an industry in the United States exists as required by the applicable Federal Statute. The amended complainant requests that the Commission institute an investigation and, after the investigation, issue a limited exclusion order and cease and desist orders.
2026-16581, Carbazole Violet Pigment 23 From China and India; Termination of Five-Year Reviews
The Commission instituted the subject five-year reviews on May 1, 2026 to determine whether revocation of the countervailing duty order on carbazole violet pigment 23 from India and the antidumping duty orders on carbazole violet pigment 23 from China and India would be likely to lead to continuation or recurrence of material injury. On August 7, 2026, the Department of Commerce published notice in the Federal Register that it was revoking the orders applicable August 7, 2026, because no domestic interested party filed a timely notice of intent to participate. Accordingly, the subject reviews are terminated.
Previous / Next Documents
Previous: 2025-14231, Agency Information Collection Activities: Office for Bombing Prevention-Technical Analytics
The Office for Bombing Prevention at CISA is asking for approval to keep collecting important info to help stop bomb threats. They already asked for feedback earlier this year but got zero comments, so now they’re giving the public 30 more days to speak up. This won’t cost anyone extra but helps keep everyone safer by improving how info is gathered and used.
Next: 2025-14233, Revocation of Emergency Use of a Drug Product During the COVID-19 Pandemic; Availability
The FDA has officially ended the emergency use of several COVID-19 antibody treatments from Regeneron, GSK, Lilly, and AstraZeneca as of December 13, 2024. This means these drugs can no longer be used under emergency rules, affecting patients and healthcare providers relying on them. The change reflects updated safety and effectiveness info, so folks should look for other treatment options moving forward.